Biotechnology News and Research

RSS

Heart failure is major public health burden in many LMICs

Heart failure is a major public health burden in many low- and middle-income countries (LMICs), with substantial variation in the presentation, causes, management, and outcomes of heart failure across different LMICs, according to a study published in this week's PLOS Medicine.

From CSL Ltd 13 Aug 2014

Sanofi, PATH announce delivery of first large-scale batches of antimalarial treatments

Sanofi and PATH today announced the delivery of the first large-scale batches of antimalarial treatments manufactured with a new semisynthetic artemisinin derivative to malaria-endemic countries in Africa.

12 Aug 2014

Synthetic Biologics' SYN-005 antibody for Pertussis treatment to be highlighted at ICAAC 2014

Synthetic Biologics, Inc., a biotechnology company developing novel anti-infective biologic and drug programs targeting specific pathogens that cause serious infections and diseases, announced today that its SYN-005 for the treatment of Pertussis will be highlighted at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy, September 5-9, in Washington D.C.

12 Aug 2014

Scientists aim to understand and treat painful bladder condition

Taking advantage of technology that can analyze tissue samples and measure the activity of thousands of genes at once, scientists at Wake Forest Baptist Medical Center are on a mission to better understand and treat interstitial cystitis (IC), a painful and difficult-to-diagnose bladder condition.

12 Aug 2014

First peer-reviewed comprehensive expert guidance on the use of neurostimulation for pain

Reflecting groundbreaking international consensus regarding a group of rapidly evolving medical interventions for chronic pain, the International Neuromodulation Society announced it will soon publish the first peer-reviewed comprehensive expert guidance on the appropriate use of neurostimulation for pain.

12 Aug 2014

Researchers create synthetic molecule that can cause cancer cells to self-destruct

Researchers from The University of Texas at Austin and five other institutions have created a molecule that can cause cancer cells to self-destruct by ferrying sodium and chloride ions into the cancer cells.

12 Aug 2014

Oncothyreon reports decreased net operating loss in Q2 2014

Oncothyreon Inc. today reported financial results for the second quarter ended June 30, 2014. Loss from operations decreased to $7.8 million for the three months ended June 30, 2014 compared with $18.0 million for the comparable period in 2013, and decreased to $15.0 million for the six months ended June 30, 2014 compared with $26.0 million for the comparable period in 2013.

12 Aug 2014

Oncothyreon acquires Alpine Biosciences to enable targeted delivery of multiple therapeutic agents

Oncothyreon Inc., a biotechnology company specializing in the development of innovative therapeutic products for the treatment of cancer, today announced that it has acquired Alpine Biosciences, Inc., of Seattle, Washington, a privately held biotechnology company developing protocells, a nanoparticle platform technology designed to enable the targeted delivery of multiple therapeutic agents, including nucleic acids, proteins, peptides and small molecules.

12 Aug 2014

Novogen receives funding support to commence studies in muscular dystrophy

The Australian biotechnology company, Novogen Limited today announced receipt of funding from the FSHD Global Research Foundation as part of the Company’s efforts to find effective treatments for a range of musculo-degenerative diseases including facioscapulohumeral dystrophy (FSHD).

11 Aug 2014

Antimalarial agent chloroquine normalizes abnormal tumor blood vessels

A recent study by investigators at VIB and KU Leuven has demonstrated that chloroquine also normalizes the abnormal blood vessels in tumors. This blood vessel normalization results in an increased barrier function on the one hand -- thereby blocking cancer cell dissemination and metastasis -- and in enhanced tumor perfusion on the other hand, which increases the response of the tumor to chemotherapy.

11 Aug 2014

Inovio Pharmaceuticals reports increased revenue in second quarter 2014

Inovio Pharmaceuticals, Inc. today reported financial results for the quarter ended June 30, 2014. Total revenue was $3.8 million and $6.2 million for the three and six months ended June 30, 2014, compared to $786,000 and $2.2 million for the same periods in 2013.

11 Aug 2014

Bio-Techne revenue increases 16% to $92.5 million in fourth quarter 2014

Techne Corporation, (d/b/a Bio-Techne) today reported its financial results for the fourth quarter and full year ended June 30, 2014.

From ProteinSimple 11 Aug 2014

3SBio enters into exclusive license with DiNonA for development of Leukotuximab

3SBio Inc., a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced it has entered into an exclusive license with DiNonA Inc. for the development, manufacturing and marketing of Leukotuximab, an anti JL-1 antibody for acute leukemia (AL), including acute myelocytic leukemia (AML) and acute lymphoblastic leukemia (ALL), in the territory of Greater China (including Mainland China, Taiwan, Hong Kong and Macau) and the Middle East (excluding Cyprus, Egypt, Israel and Turkey).

8 Aug 2014

Vitro toxicity testing an alternative to predict adverse health effects of drugs

In vitro toxicity testing is rapidly being adopted in the pharmaceutical, chemical, and cosmetics industries, for example, as an alternative to animal studies to predict adverse health effects of drugs and personal care products and the health consequences of environmental exposures.

8 Aug 2014

CTBC Bank donates $200,000 to Huntsman Cancer Foundation

CTBC Bank (USA) and its parent company CTBC Financial Holdings have donated $200,000 as a global partner to the Huntsman Cancer Foundation, which kicks off its new annual Championship for Cancer Research fundraiser.

7 Aug 2014

Oncolytics Biotech announces financial results and operational highlights for second quarter 2014

Oncolytics Biotech Inc. today announced its financial results and operational highlights for the second quarter ended June 30, 2014.

7 Aug 2014

Soligenix demonstrates improved immunogenicity and rapid action of anthrax vaccine, VeloThrax

Soligenix, Inc., a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, announced today results demonstrating the improved immunogenicity and rapid action of its anthrax vaccine, VeloThrax™.

7 Aug 2014

Auxilium Pharmaceuticals' total revenues decrease 17% to $83 million in Q2 2014

Auxilium Pharmaceuticals, Inc., a fully integrated specialty biopharmaceutical company, today announced financial results for the second quarter ending June 30, 2014. The Company highlighted important corporate, commercial, regulatory and clinical development updates from the quarter.

7 Aug 2014

UCSF researchers identify novel molecular features within the developing human brain

UC San Francisco researchers have identified cells' unique features within the developing human brain, using the latest technologies for analyzing gene activity in individual cells, and have demonstrated that large-scale cell surveys can be done much more efficiently and cheaply than was previously thought possible.

7 Aug 2014

New reporting standards proposed for spinal cord injury experiments

The difficulty in replicating and directly comparing and confirming the scientific results reported by researchers worldwide who are studying new approaches to treating spinal cord injuries is slowing the translation of important new findings to patient care.

7 Aug 2014

Biotechnology News and Research

Heart failure is major public health burden in many LMICs

Sanofi, PATH announce delivery of first large-scale batches of antimalarial treatments

Synthetic Biologics' SYN-005 antibody for Pertussis treatment to be highlighted at ICAAC 2014

Scientists aim to understand and treat painful bladder condition

First peer-reviewed comprehensive expert guidance on the use of neurostimulation for pain

Researchers create synthetic molecule that can cause cancer cells to self-destruct

Oncothyreon reports decreased net operating loss in Q2 2014

Oncothyreon acquires Alpine Biosciences to enable targeted delivery of multiple therapeutic agents

Novogen receives funding support to commence studies in muscular dystrophy

Antimalarial agent chloroquine normalizes abnormal tumor blood vessels

Inovio Pharmaceuticals reports increased revenue in second quarter 2014

Bio-Techne revenue increases 16% to $92.5 million in fourth quarter 2014

3SBio enters into exclusive license with DiNonA for development of Leukotuximab

Vitro toxicity testing an alternative to predict adverse health effects of drugs

CTBC Bank donates $200,000 to Huntsman Cancer Foundation

Oncolytics Biotech announces financial results and operational highlights for second quarter 2014

Soligenix demonstrates improved immunogenicity and rapid action of anthrax vaccine, VeloThrax

Auxilium Pharmaceuticals' total revenues decrease 17% to $83 million in Q2 2014

UCSF researchers identify novel molecular features within the developing human brain

New reporting standards proposed for spinal cord injury experiments

Industry Focus eBook - Biotechnology (4th edition) eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News